2026 Employee Benefits: Managing GLP-1 & Drug Costs

Every year, the benefits industry publishes a wave of cost projections and planning guides. And every year, the numbers move in the same direction: up. But 2026 is different in kind, not just degree. The convergence of GLP-1 medication demand, specialty drug pipeline expansion, and post-pandemic utilization increases has created a cost environment that most employers haven’t seen in over a decade.

The numbers tell the story. Employers are projecting an 8% to 10% increase in health care costs for 2026, according to research from the International Foundation of Employee Benefit Plans and multiple industry surveys. That’s up from the 6% to 8% range projected just a year earlier. National prescription drug spending grew 10% in 2024 alone, and GLP-1 medications are now estimated to account for 14% of all prescription drug spending in 2026.

For brokers, this creates a dual challenge. Your employer clients need strategies to contain costs. But they also can’t afford to strip benefits that employees increasingly expect, especially in a labor market where benefits packages are a primary differentiator for talent. The question isn’t whether to address GLP-1 and specialty drug costs. It’s how to do it without undermining the very benefits that make your clients competitive employers.

1. The GLP-1 Cost Problem: Bigger Than Most Employers Realize

GLP-1 receptor agonists like Ozempic, Wegovy, Mounjaro, and Zepbound have reshaped the treatment landscape for both diabetes and obesity. Their clinical results are significant. But their cost profile is challenging employers across every size tier. Net prices for a 30-day supply currently range from $617 to $766 per patient, and most patients need to stay on the medication indefinitely to maintain results. According to research from the Employee Benefit Research Institute, more than 57 million privately insured adults are clinically eligible for GLP-1 drugs based on diagnoses of diabetes, obesity, or being overweight with additional risk factors.

The demand side is accelerating. GLP-1 drug claims rose from 6.9% of employer plans in 2023 to 10.5% in 2025, according to Blue Cross Blue Shield data. Nearly one in eight adults now reports taking a GLP-1 for weight loss or chronic condition management. And with oral formulations from Novo Nordisk and Eli Lilly expected within the next 12 to 18 months, utilization is likely to increase further as the injection barrier drops.

The coverage dilemma in numbers

Two-thirds of large employers now cover GLP-1s for weight management, according to the Business Group on Health. But only 72% of those plan to maintain that coverage into 2027. Meanwhile, 77% of large employers say managing GLP-1 costs is extremely or very important. The gap between coverage expectations and cost sustainability is widening.

The adherence picture adds another wrinkle. Nearly two-thirds of patients discontinue GLP-1 treatment before reaching the 12-week mark needed for meaningful weight loss, and more than 40% stop after just four weeks. That means employers are absorbing significant pharmacy costs without consistently seeing the health outcomes that would justify the investment through reduced downstream medical spending.

2. Specialty Drugs and the Broader Cost Surge in Employer Benefits

GLP-1s get the headlines, but they’re part of a broader specialty drug trend that’s reshaping employer health care cost trends for 2026 and beyond. Autoimmune therapies, gene therapies, oncology biologics, and rare disease treatments are all contributing to a pharmacy cost trajectory that’s outpacing medical inflation.

Clinical drug infusions rose 14% in 2024, outpacing even the overall 10% growth in national drug spending. Cell and gene therapies, while still affecting a small number of patients, can carry per-treatment costs exceeding $500,000, creating catastrophic claims risk that disproportionately impacts smaller employer groups with less capacity to absorb outlier costs.

The combined effect is an employee benefits cost environment where medical and prescription benefits are projected to increase 8% to 10% in 2026, according to HUB International’s research. For employers who are also navigating post-pandemic utilization increases in mental health and substance abuse services, the budget pressure is coming from multiple directions simultaneously.

Half of large employers are now likely or very likely to shift more costs to employees in 2026, up from 45% who said the same about 2025. That includes raising deductibles, increasing out-of-pocket maximums, and restructuring cost-sharing arrangements. The risk for brokers: if cost-shifting is the only strategy on the table, employee satisfaction and talent retention suffer.

3. GLP-1 Coverage Strategies That Balance Cost and Talent

The employers navigating this well aren’t choosing between covering GLP-1s and controlling costs. They’re designing smarter coverage frameworks that manage spend while preserving the benefit as a talent differentiator. Here are the strategies gaining traction.

Clinical eligibility gating with biometric validation. Rather than open access or blanket exclusions, leading employers are tying GLP-1 coverage to objective clinical criteria: BMI thresholds, documented comorbidities, and biometric screening data. This narrows the eligible population to those most likely to benefit clinically while maintaining coverage for employees who genuinely need it.

Mandatory lifestyle program pairing. Some employers are requiring participation in structured weight management or behavioral health programs as a condition of GLP-1 coverage. The logic is sound: patients who receive consistent follow-up, nutritional guidance, and behavioral support show better adherence and outcomes. This approach improves ROI per patient while signaling that the employer is investing in comprehensive health, not just prescriptions.

Specialty pharmacy carve-outs. Directing GLP-1 prescriptions through specific vendors or specialty pharmacies can improve pricing transparency and rebate capture. As PBMs adjust their GLP-1 strategies in response to resolved supply constraints, brokers who understand the rebate landscape can help clients negotiate better terms without reducing coverage.

Tiered cost-sharing that preserves access. Moderate copay increases (in the $60 to $90 range per fill) can reduce premium impact by 1 to 2 percentage points without eliminating coverage entirely. The key is designing the cost-share to discourage casual use while keeping the medication affordable for employees who are clinically committed to treatment.

Monitoring the pipeline for alternatives. Nearly 150 obesity-related drugs are currently in development, and the market will look very different in two to three years. Oral GLP-1 options, next-generation compounds targeting different pathways, and eventually generic versions of current products will create new pricing leverage. Brokers who stay ahead of the pipeline can advise clients on when to expand or restructure coverage based on emerging options.

The talent angle brokers can’t ignore

Removing GLP-1 coverage entirely may save money in the short term, but it carries real talent risk. Employees value these benefits, and in a competitive labor market, a benefits reduction is a retention risk. The broker’s role is to help clients find the middle ground: coverage frameworks that are financially sustainable and still attractive to current and prospective employees.

4. How Brokers Use Data to Model Better Alternatives

The strategies above sound straightforward in concept. In practice, they require data that most brokers don’t have at their fingertips: carrier-level pricing comparisons, plan design benchmarks across size tiers, utilization patterns by product category, and the ability to model how different coverage configurations affect total plan cost.

This is where the conversation shifts from general industry advice to practical broker advantage. The brokers winning in the current environment aren’t just reading the same outlook reports and passing projections to their clients. They’re using benefits intelligence platforms to run specific scenarios: what happens to total plan cost if we add a $75 copay on GLP-1s? How does this client’s pharmacy spend compare to similar employers in their size tier and region? Which carriers are offering better terms on specialty drug management right now?

That kind of analysis turns a broker from a plan administrator into a strategic advisor. And it’s the difference between telling a client that costs are going up 10% and showing them three specific scenarios for bringing that number down to 6% or 7% without gutting the benefits their employees care about. BenefitFlow’s platform is built for exactly this kind of work, giving brokers access to carrier ratings, plan benchmarks, and market intelligence across thousands of employers to support data-driven recommendations that hold up in client conversations.

The point isn’t to replace broker judgment with a dashboard. It’s to arm broker judgment with the data that makes it defensible, specific, and actionable. When you walk into a renewal meeting with three modeled alternatives instead of a single carrier quote, you’re a different kind of broker.

5. What to Tell Your Clients Right Now

If you’re heading into renewal season conversations, here are the talking points that position you as a strategic partner rather than a cost messenger.

Lead with the market context, not just the premium increase. Most employers are seeing 8% to 10% increases this cycle, driven primarily by pharmacy costs and GLP-1 utilization. Your client isn’t being singled out. But you can help them respond better than most.

Frame GLP-1 management as a design question, not a yes-or-no question. The conversation shouldn’t be “do we cover GLP-1s or not.” It should be “how do we cover them in a way that’s clinically appropriate, financially sustainable, and competitive for talent.” That reframe positions you as the strategic thinker, not the bearer of bad news.

Present alternatives with data, not opinions. Show your client how their plan design, carrier terms, and pharmacy management compare to benchmarks. Bring two or three specific restructuring options with projected cost impacts. Employers trust brokers who bring receipts.

Connect benefits strategy to talent strategy. Remind your clients that benefits aren’t just a cost line. They’re a competitive tool. The employers who maintain strong, well-designed benefits through this cost cycle will be better positioned to attract and retain talent on the other side of it. That’s a message that resonates in the C-suite.

The Broker Opportunity in the Cost Crunch

Rising employee benefits costs are a headache for employers. For brokers, they’re an opportunity. The employers feeling the most pressure are the ones most likely to engage with a broker who can do more than pass along a renewal number. They want someone who understands the GLP-1 landscape, can model alternatives, and can help them navigate the tension between cost containment and talent competitiveness.

That’s the role that separates a benefits broker from a benefits advisor. And in a year where health care cost trends are running at 8% to 10% and climbing, the advisors are the ones who will grow their books.

Benchmark Your Clients’ Plans

BenefitFlow gives brokers the carrier ratings, plan benchmarks, and market intelligence needed to have smarter renewal conversations. See how your clients’ benefits compare and model cost-saving alternatives with real data. Visit benefitflow.com to learn more or request a demo.

Additional Resources

Sources for statistics cited in this article include SHRM, EBRI, HUB International, KFF, Mercer, Blue Cross Blue Shield Association, and the Business Group on Health. All data reflects the most recent available research as of publication.

2026 Employee Benefits Outlook: Managing GLP-1 and Specialty Drug Costs